ClinicalTrials.gg
CompletedNCT05247203Updated Dec 6, 2023

Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

A Phase 1 interventional study of Telitacicept and standard therapy in Systemic Lupus Erythematosus, sponsored by RemeGen Co., Ltd.. Completed at 19 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by RemeGen Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing telitacicept in Lupus Erythematosus, Systemic — 6 open to participants now, 7 under way, 1 of them phase 3. telitacicept · Lupus Erythematosus, Systemic.

Enrollment
5th of 13
92 · median 64
Started
2022
with 3 others
Phase 1
2 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
4 of 13
RemeGen Co., Ltd.

Among the 13 studies testing telitacicept in Lupus Erythematosus, Systemic, this one is the 5th largest by enrollment, is one of 4 that started in 2022, is one of 2 in phase 1, and was the 3rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

6 of the 13 studies testing telitacicept in Lupus Erythematosus, Systemic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About telitacicept

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing telitacicept in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This is a multi-center, open-label, phase I study.

Read the detailed description

The purpose of this study is to evaluate the pharmacokinetics, safety and efficacy of Telitacicept in Chinese patients with systemic lupus erythematosus.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus
  • Telitacicept
  • Pharmacokinetics
  • Lupus Erythematosus, Systemic
  • Connective Tissue Diseases
  • Autoimmune Diseases
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who give consent to this study participation and sign form;
  2. Males and females, between the ages of 18 and 65 years old, inclusive, at the screening visit;
  3. Diagnosis of SLE as defined by the American College of Rheumatology (ACR) 1997 criteria, with 4 or more of the 11 ACR criteria present;
  4. SELENA-SLEDAI score ≥8 points with a clinical SELENA-SLEDAI score ≥6 points if low complement levels and/or anti-ds-DNA antibodies are present at the screening visit;
  5. Subjects with unequivocally positive test for anti-nuclear antibody (ANA) and/or anti-ds-DNA serum antibody;
  6. Be on a SLE standard treatment regimen (and remain stable) for a period of at least 30 days prior to Day 0. The standard regimen consists of the following medication(s) (alone or in combination):, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with severe lupus kidney disease (defined by proteinuria >6g/24h or serum creatinine >2.5mg/dL or serum creatinine >221μmol/L) or active nephritis requiring prohibited medications, or subjects requiring hemodialysis or prednisone (or its equivalent)≥100mg/d for a period of ≥14 days within 8 weeks of Day 0;
  2. Central nervous system (CNS) disease associated with lupus or not [including seizures, psychosis, organic brain syndrome, cerebrovascular accident (CVA), encephalitis, CNS angiitis] within 8 weeks prior to the screening visit;
  3. Laboratory abnormalities including, but not limited to the following:

    1. /AST≥2× (ULN);
    2. endogenous rate\<30 mL/min;
    3. white blood cell count\<2.5×10\^9/L;
    4. \<85 g/L;
    5. count\<50×10\^9/L;
  4. Active hepatitis or a history of severe liver disease at the screening visit. Positive test for surface antigen (HBsAg) or anti- virus antibodies (HCVAb). If anti-HBcAb result is positive while HBsAg result is negative, hepatitis B virus (HBV)-(DNA) test will be performed. If HBV-DNA result is negative, the patient is eligible;
  5. Subjects with immunodeficiency, uncontrolled severe infection or active/recurrent gastrointestinal ulcers;
  6. Pregnant or lactating female subjects or sexually active subjects who refuse to practice the protocol-specified throughout the study;
  7. History of allergy to humanized biological products;
  8. Subjects who received within 28 days of Day 0;
  9. Participation in any other study drug trial in the past 28 days or 5 half-lives, whichever was longer, prior to Day 0. Subjects who participated in a clinical trial on B-cell-targeted drug, or tumor necrosis factor inhibitor, or interleukin receptor blocker within 12 months prior to Day 0 would be excluded;
  10. Subjects who received other B-cell targeted drugs, such as Belimumab, rituximab or Epratuzumab within 12 months prior to Day 0;
  11. Subjects who received tumor necrosis factor inhibitors, interleukin receptor blockers within 12 months prior to Day 0;
  12. Subjects who received intravenous immune globulin (IVIG), or high dose prednisone or its equivalents (≥100mg/d) for a period of ≥ 14 days, or plasma exchange within 28 days prior to Day 0;
  13. Subjects who received IL-2, Thalidomide, Tripterygium wilfordii or Chinese medicinal preparations containing Tripterygium wilfordii within 28 days prior to Day 0;
  14. Subjects with active infections (herpes zoster, infection, active tuberculosis, etc.) at the screening visit;
  15. Subjects with depression or suicidal thoughts;
  16. Any condition or circumstance that, in the opinion of the investigator, may compromise the patient's ability to comply with the study protocol..
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Telitacicept Arm 1

    Telitacicept 80mg, once a week for 24 weeks plus standard therapy

    Biological: Telitacicept · Drug: standard therapy

  • Experimental
    Telitacicept Arm 2

    Telitacicept 160mg, once a week for 24 weeks plus standard therapy

    Biological: Telitacicept · Drug: standard therapy

  • Experimental
    Telitacicept Arm 3

    Telitacicept 160mg, once a week for 12 weeks followed by once every two weeks for another 12 weeks plus standard therapy

    Biological: Telitacicept · Drug: standard therapy

  • Experimental
    Telitacicept Arm 4

    Telitacicept 240mg, once a week for 24 weeks plus standard therapy

    Biological: Telitacicept · Drug: standard therapy

  • Experimental
    Telitacicept Arm 5

    Telitacicept 240mg, once every two weeks for 24 weeks plus standard therapy

    Biological: Telitacicept · Drug: standard therapy

Interventions

  • BiologicalTelitacicept

    subcutaneous injection

    Also known as: RC18

  • Drugstandard therapy

    A standard regimen consists of the following medication(s) (alone or in combination):corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax) of Telitacicept

    Cmax is defined as peak plasma concentration of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  2. Time to reach Cmax (tmax) of Telitacicept

    tmax is defined as time to reach Cmax of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  3. Observed plasma concentration of Telitacicept just prior to the beginning of a dosing interval (Ctrough)

    Ctrough is defined as observed plasma concentration of Telitacicept just prior to the beginning of a dosing interval

    Time frame: up to 42 days following the last dose of Telitacicept

  4. Average concentration (Cav) of Telitacicept

    Average concentration of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  5. Area under the curve from time zero to last quantifiable concentration (AUC 0-t) of Telitacicept

    AUC 0-t is defined as area under the curve from time zero to last quantifiable concentration of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  6. Area under the curve from time zero to tau (AUC 0-tau) of Telitacicept

    AUC 0-tau is defined as area under the curve from time zero to tau of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  7. Terminal elimination rate constant (λz) of Telitacicept

    λz is defined as terminal elimination rate constant

    Time frame: up to 42 days following the last dose of Telitacicept

  8. Terminal elimination half-life (t1/2z) of Telitacicept

    t1/2z is defined as terminal elimination half-life of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  9. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Telitacicept

    Vz/F is defined as apparent volume of distribution during the terminal phase after extravascular administration of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  10. Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of Telitacicept

    CL/F is defined as apparent total body clearance of drug from plasma after extravascular administration of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

Secondary outcomes

  1. Percentage of participants achieving a SLE Responder Index (SRI)

    Percentage of subjects with a ≥ 4 point reduction from baseline in SELENA-SLEDAI score, and no worsening (increase of \< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.

    Time frame: Week 4, 8, 12, 16, 20, and 24

  2. Percentage of participants achieving a SELENA-SLEDAI improvement of ≥4 points

    SELENA-SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105.

    Time frame: Week 4, 8, 12, 16, 20, and 24

  3. Change From Baseline to W24 in patient global assessment (PGA)

    PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).

    Time frame: Week 4, 8, 12, 16, 20, and 24

  4. Change From Baseline to W24 in IgG

    Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.

    Time frame: Week 4, 8, 12, 16, 20, and 24

  5. Change From Baseline to W24 in IgA

    Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.

    Time frame: Week 4, 8, 12, 16, 20, and 24

  6. Change From Baseline to W24 in IgM

    Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.

    Time frame: Week 4, 8, 12, 16, 20, and 24

  7. Change From Baseline to W24 in C3

    Complement (C3/C4) are proteins that are part of the immune system.

    Time frame: Week 4, 8, 12, 16, 20, and 24

  8. Change From Baseline to W24 in C4

    Complement (C3/C4) are proteins that are part of the immune system.

    Time frame: Week 4, 8, 12, 16, 20, and 24

  9. Number of Participants Experiencing Adverse Events (AEs)

    Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

    Time frame: up to 28 days following the last dose of Telitacicept

07

Study locations

19 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • The First Affiliated Hospital of University of Science and Technology of China
    Hefei, Anhui 230001, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510260, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541001, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Xiangya Hospital, Central South University
    Changsha, Hunan 410008, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264200, China
  • The Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030032, China
  • General Hospital of Tianjin Medical University
    Tianjin, Tianjin 300052, China
  • The People's Hospital of Xinjiang Uygur Autonomous Region
    Ürümqi, Xinjiang 830001, China
  • The First People's Hospital of Yunnan Province
    Kunming, Yunnan 650011, China
  • The Second Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Oct 2023, 17 months.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 17 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2022
First posted
Feb 18, 2022
StartActual
May 11, 2022
Primary completionActual
Oct 25, 2023
CompletionActual
Nov 13, 2023
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05247203
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
May 11, 2022
Primary completion
Oct 25, 2023
Completion
Nov 13, 2023
Last update
Dec 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion